NCT04526496View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetics of FTP-198 in Healthy Australian Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

February 24, 2020

Primary Completion Date

November 5, 2020

Study Completion Date

November 5, 2020

Conditions
Healthy
Interventions
DRUG

FTP-198, single dose

Single dose of FTP-198, 6 dose levels, oral suspension

DRUG

Placebo, single dose

Placebo matched to FTP-198, oral suspension

DRUG

FTP-198, multiple doses

Multiple doses of FTP-198, 3 dose levels, oral suspension, 7 days

DRUG

Placebo, multiple doses

Placebo matched to FTP-198, oral suspension, 7 days

Trial Locations (1)

Unknown

CMAX Clinical Research Pty Ltd, Adelaide

All Listed Sponsors
lead

Sichuan Haisco Pharmaceutical Group Co., Ltd

INDUSTRY

NCT04526496 - Safety, Tolerability and Pharmacokinetics of FTP-198 in Healthy Australian Volunteers | Biotech Hunter | Biotech Hunter